NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 09:31:30 2024-05-31 am EDT			5-day change	1st Jan Change
0.8126 ^USD	-0.54%		+4.72%	-29.34%

May. 22	NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan	CI
May. 15	NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

NanoVibronix, Inc. Announces Partnership with Peak Medical, Ltd

December 13, 2022 at 08:30 am EST

NanoVibronix, Inc. announced that it has partnered with Peak Medical Ltd. Leading UK Manufacturer and Distributor of Continence Care Products Expands Distribution Capabilities Following Recent NHS Supply Chain Approval.

Latest news about NanoVibronix, Inc.

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan	May. 22	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
NanoVibronix Signs Multiyear Distribution Deal With CB Medical for UroShield	May. 14	MT
NanoVibronix, Inc. Announces Distribution Agreement with Cb Medical, Llc for the Distribution of Uroshield	May. 14	CI
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs? FSS Contract Award	May. 01	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	Dec. 04	CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	Nov. 28	CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket	23-10-20	MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff	23-09-27	CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders	23-09-13	MT
NanoVibronix to Raise $5 Million Through Securities Placement	23-08-30	MT
Top Midday Gainers	23-08-30	MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding	23-08-29	CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device	23-08-29	MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff	23-08-28	CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise	23-08-23	MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus	23-08-23	CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
NanoVibronix Announces Distribution Agreement with Mio-Guard	23-06-14	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services	23-03-28	CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump	23-03-21	MT

Chart NanoVibronix, Inc.

Duration

Period

More charts

Company Profile

NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOVIBRONIX, INC.	-29.34%	2.27M
ABBOTT LABORATORIES	-7.15%	177B
BECTON, DICKINSON AND COMPANY	-6.54%	65.54B
DEXCOM, INC.	-2.71%	47.09B
CENCORA, INC.	+7.91%	43.43B
HOYA CORPORATION	+8.14%	41.77B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.61%	29.55B
TERUMO CORPORATION	+15.53%	24.83B
WEST PHARMACEUTICAL SERVICES, INC.	-6.10%	23.97B
ZIMMER BIOMET HOLDINGS, INC.	-5.91%	23.54B

Other Medical Equipment, Supplies & Distribution